High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre
Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl KM, Arnold G
Published in European Journal of Neurology
Methodology
Open-label study of riboflavin 400 mg daily for up to six months in 23 migraine patients at a tertiary headache centre.
Key Findings
Mean headache frequency fell from four to two attacks per month and abortive medication use decreased.
Conclusions
Open-label data support high-dose riboflavin as prophylaxis, but placebo response cannot be excluded.
Limitations
Open-label, uncontrolled, small tertiary-referral sample.
Supplements Studied
Mean headache frequency fell from four to two attacks per month during open-label high-dose riboflavin.
Outcomes Measured
Headache frequency fell from four to two attacks per month with abortive medication use decreasing.
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.